IPR Tracker: IPR2016-00408 & IPR2016-00409 (U.S. Patent No. 8,889,135) (Boehringer Ingelheim Int’l GMBH) – IPRs Instituted

Goodwin
Contact
LinkedIn
Facebook
X
Send
Embed

The Board has instituted IPR2016-00408 and IPR2016-00409 on AbbVie Biotechnology’s U.S. Patent No. 8,889,135, which covers methods of treating rheumatoid arthritis with a human anti-tumor necrosis factor α antibody. This patent relates to AbbVie’s Humira®.

IPR2016-00172 filed by Coherus BioSciences Inc. was also instituted against this patent earlier this year.

Send Print Report

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Goodwin | Attorney Advertising

Written by:

Goodwin
Goodwin
Contact
more
less

Goodwin on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign Up Log in
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide
- hide